Cell Cycle

• 1893 · PDF Inhibiting CDK9/13 decreases progression of multiple myeloma and myeloma-induced bone disease in preclinical studies Tiina E. Kähkönen, Gergana Gababova, Ru Yang, Jie Wen, Michael Thormann, Jussi M. Halleen
• 1894 · PDF Proteome-wide target engagement and selectivity profiling of CDK2 inhibitors using CETSA® Tomas Friman, Merve Kacal, Tuomas Tolvanen
• 1895 · PDF Distinct metabolic adaptations to resistance to CDK4/6 inhibitors in ER+ breast cancer identified using microfluidic mass spectrometry platform Gianna A. Slusher, Yuan Gu, Sunil S. Badve, Andrei G. Fedorov, Yesim Gökmen-Polar
• 1896 · PDF ‘Translating' CDK9 inhibitor effects to target prostate cancer Shivani Yalala, Pedro Durao, Agata Carreira, Joyeeta Chatterjee, Muskan Kumari, Antti Sakari Rannikko, Eileen E. Parkes, Fadi Issa, Ian G. Mills, Harri M. Itkonen
• 1897 · PDF Targeting RB-deficient small cell lung cancer with selective CDK2 inhibition by AZD8421 Rajita Vatapalli, Michael Grondine, Jun Fan, Grace Guo, Zhan Liu, Tam Nguyen, Deepa Bhavsar, Christopher Denz
• 1899 · PDF Thymidine kinase activity as a translational biomarker to support dose optimization in oncology drug development and a tool for monitoring patients Hanna Ritzén, Mattias Bergqvist
• 1900 · PDF PTEN loss of function encodes sensitivity to multitargeted small molecule CDK4/6-CDK9-AURKA/B inhibitor, LCI133, and other CDK9 inhibitors Halle Goodwin, Qi Zhang, Vaidehi Mujumdar, Krishaniah Maddeboina, Cody McHale, Bharath Yada, Hailey Dryden, Robert Wendel Naumann, Yovanni Casablanca, Erin K. Crane, Jubilee Brown, Allison Puechl, Brittany Lees, Donald Durden, Dhananjaya Pal
• 1901 · PDF Mechanisms of sensitivity and resistance to CDK2 inhibitors Sabrina L. Spencer
• 1902 · PDF Comparative biochemical evaluation of small-molecule inhibitor efficacy on CDK/Cyclin complexes across diverse mammalian species Andreas Gericke, Frank Totzke, Constance Rademann, Carolin Heidemann-Dinger, Daniel Mueller
• 1903 · PDF Targeting autophagy and the cell cycle in mesothelioma George Scaria, Marian Kratzke, Stephen Porter, Betsy Kren, Mark A. Klein
• 1904 Dual-targeting CDK4 and CDK2 overcomes resistance to CDK4/6 inhibitors in HR+ breast cancer Wenqing Cai, Siwen Liu, Lu Su, Quang Fu, Chen Liao
• 1905 · PDF Discovery of ABK-CDK4, a selective and brain-penetrant CDK4 inhibitor Weiling Pan, Hui Wang, Fangfei Qi, Zheng Li, Xinming Du, Jie Zhang, Jie Wang, Manqi Zhang, Haibing Deng, Hongping Yu, Yao-chang Xu, Haiyan Ying
• 1906 · PDF Novel treatment: CDK11 inhibition in rhabdoid tumor of the kidney Kamhung Lam, Yuki Murakami, Shinsuke Fukui, Elizabeth Helmke, Noriko Satake
• 1907 · PDF CDK2 controls RIPK2 ubiquitination and stability in prostate cancer cells Lili M. Guerra, Ahmed M. Elgehama, Jaceline G. P. Sanches, Leslie Chiu, Wei Yang*
• 1908 · PDF Activity of dual BET and CDK9 inhibition in murine models of pancreatic ductal adenocarcinoma Michela Cadarso, Austin Stram, Lucas Koeppel, Robert J. Millikin, Md Shahadat Hossan, Eleanor Riedl, Ron Stewart, Jeremy D. Kratz
• 1909 CDK7 inhibition by SY5609 suppresses tumor growth in gastric cancer through inhibiting RNA pol II mediated transcription and Hippo/YAP1 signaling Dipti Athavale, Yan-ting Yann Zhang, Mikel Ghelfi, Anthony Pompetti, Junsong Zhao, Xiaodan Yao, Shumei Song
• 1910 · PDF GDC-4198, a next-generation CDK4/2 inhibitor, induces durable cell cycle arrest and shows combination benefit with giredestrant Marc Hafner, Steffan Vartanian, Luca Gerosa, Nont Kosaisawe, Michael S. Hwang, Eva Lin, Yi-Chang Wang, Jason Oeh, Tianyi Chen, Kazi N. Islam, Alice Zheng, Karen Samy, Udi Segal, John G. Moffat, DANIEL ZINGG, Annie Collier, Ioannis Sanidas, Zhi Xie, Seth A. Wander
• 1911 · PDF Targeting PLK1 or WEE1 uncovers a therapeutic vulnerability in BRCA1/2 wild-type, homologous recombination-proficient high-grade serous ovarian cancer Akiko Kunita, Qian Xi, Masanori Kawakami, Miho Ogawa, Mirei Ka, Kousuke Watanabe, Tetsuo Ushiku, Hidenori Kage, Kazuhiro Katayama, Katsutoshi Oda
• 1912 · PDF Extrachromosomal DNA (ecDNA)-mediated replication stress as a potential targetable vulnerability in high-risk medulloblastoma Jessica Wang, Hui Hui, Jon D. Larson, Rishaan Kenkre, Owen Chapman, Yan Yuen Lo, Emerald Adeyan, Lukas Chavez
• 1913 · PDF KMT2D deficiency alters CDK-cyclin regulation of Rb in endometrial cancer Madelyn Maurer, Swornalata Pukhrambam, Jessica Long, Sanjeev Ganesh, Sophia Agrusa, Maya Paytas, Katherine Gurdziel, Paul Stemmer, Mike R. Wilson
• 1914 · PDF Sequential inhibition of CDK4/6 and the mitotic kinase TTK as a potential treatment in triple-negative breast cancer cell lines Gretchen M. Albarrán-Acosta, Janangelis López-Ramos, Magda N. Álvarez-Rodríguez, Alexandra N. Aquino-Acevedo, Harold I. Saavedra-Lugo
• 1915 · PDF Serpine2 promotes melanoma progression through the modulation of the DDX3X/MITF/p21 signaling pathway Qirui Liu, Xin Huang, Xiao Zhang, Xinyu Ye, Yi Lu, Jian Zhang
• 1916 · PDF Identifying changes in cell cycle regulatory proteins during clobetasol-induced quiescence in UMSCV-4 vulvar cancer cells Claudia M. Marsello, Trinity A. Trojanowski, Jani E. Lewis
• 1918 · PDF CRISPR screening in human iPSC-derived glioblastoma models reveals RNA-binding protein dependencies associated with TERT promoter mutation Christopher C. Chie, Daisuke Kawauchi, Shunichiro Miki, Nicholas O. Stevers, Joseph F. Costello, Chun-Yuan Chen, Gene W. Yeo, Frank B. Furnari
• 1919 · PDF Longer leukocyte telomeres and specific alleles of telomere maintenance genes are independently associated with improved survival of colon cancer patients Estela M. Cruz Garcia, Gobinda Sarkar, Jun Chen, Shubham Sood, Kim Kossick, Daniel Schupack, Rondell Graham, Brooke Druliner, Zahra Heydari, Lauren Helgeson, Richard G. Cawthon, Lisa A. Boardman
• 1920 · PDF Resolving telomere length dynamics in breast cancer evolution through single-cell DNA sequencing Nicolaas Baudoin, Lei Yang, Chenling Tang, Hanghui Ye, Kaile Wang, Jianzhuo Li, Yun Yan, Nicholas E. Navin
• 1921 Proximity labeling and thermal profiling proteomic analysis unveil mechanistic role of YWHAZ and YWHAB in CDK4/6 inhibitor resistance Min‑Jyun Dong, Wei-Ting Chung, Yi-Ru Tseng, Chun-Yu Liu, Chi-Cheng Huang, Ling-Ming Tseng, Ta-Chung Chao, Jiun-I Lai

在完整检索应用中浏览本分会场 →